Logotype for Innovative Industrial Properties Inc

Innovative Industrial Properties (IIPR) Q4 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Innovative Industrial Properties Inc

Q4 2025 earnings summary

6 Aug, 2026

Executive summary

  • Diversified REIT with $2.5 billion in invested capital, operating across cannabis and life sciences in 19 U.S. states with 111 properties and over 35 tenants.

  • 2025 marked by disciplined execution, strong balance sheet, and strategic repositioning for long-term growth, with $266 million in total revenues and $114.4 million net income attributable to common stockholders.

  • Over $1.1 billion returned to shareholders via dividends since inception, reflecting a durable business model and robust dividend growth.

  • Strategic $270 million investment in life sciences via IQHQ, with $150 million funded by year-end 2025 and $120 million remaining to be committed through 2027.

  • Significant progress made in re-tenanting and resolving non-performing assets, with legal wins, new leases signed, and settlement payments received from defaulted tenants.

Financial highlights

  • 2025 total revenues reached $266 million; AFFO was $205.4 million ($7.24 per share); Q4 2025 revenues were $66.7 million, with AFFO of $53.3 million ($1.88 per share).

  • AFFO per share (annualized Q4 2025): $7.52; dividends per share (annualized Q4 2025): $7.60.

  • Net income attributable to common stockholders Q4 2025: $30.7 million ($1.06 per share); full-year 2025: $114.4 million ($3.93 per share).

  • Over $145 million raised in debt and preferred equity since October 2025, including a new $100 million revolving credit facility.

  • Exited 2025 with liquidity exceeding $105 million.

Outlook and guidance

  • Over $40 million in preferred stock raised in early 2026 at a yield of just over 9.5%.

  • Committed to funding up to an additional $120 million in preferred equity to IQHQ through 2027.

  • U.S. legal cannabis market projected to grow at 7% CAGR from 2024–2029, reaching $44 billion by 2029.

  • Confident in long-term fundamentals of the life science sector and expect sustained demand for specialized real estate.

  • Anticipate further earnings upside as re-tenanting and legal resolutions are realized in future quarters.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more